[Skip to Content]
[Skip to Content Landing]
Viewpoint
May 20, 2020

Coronavirus Disease 2019 (COVID-19) and Immune-Engaging Cancer Treatment

Author Affiliations
  • 1Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee
  • 2Division of Infectious Diseases, Department of Medicine, Medical College of Wisconsin, Milwaukee
  • 3Department of Internal Medicine, Jinnah Postgraduate Medical Center, Karachi, Pakistan
  • 4Department of Otolaryngology–Head and Neck Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland
JAMA Oncol. 2020;6(10):1529-1530. doi:10.1001/jamaoncol.2020.2367

The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is currently intensifying across the world. The US alone accounts for nearly one-third of the global disease burden and approximately one-fifth of deaths. The number of reported cases has been doubling weekly in the US, emphasizing the contagiousness of the disease among the US population due to a lack of immunity to the novel virus.1

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    ×